The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
Open accessAbstract
In a previous study we applied a three-step avidin–biotin pretargeting approach to target 90Y-biotin to the tumour in patients with recurrent high grade glioma. The encouraging results obtained in this phase I–II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival. We enrolled 37 high grade glioma patients, 17 with grade III glioma and 20 with glioblastoma, in a controlled open non-randomized study. All patients received surgery and radiotherapy and were disease-free by neuroradiological examinations. Nineteen patients (treated) received adjuvant treatment with radioimmunotherapy. In the treated glioblastoma patients, median disease-free interval was 28 months (range=9–59); median survival was 33.5 months and one patient is still without evidence of disease. All 12 control glioblastoma patients died after a median survival from diagnosis of 8 months. In the treated grade III glioma patients median disease-free interval was 56 months (range=15–60) and survival cannot be calculated as only two, within this group, died. Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly in glioblastoma where it impedes progression, prolonging time to relapse and overall survival. A further randomized trial is justified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bootstrap Methods and their Application
Davison, A. C., & Hinkley, D. V. (1997) · doi:10.1017/cbo9780511802843 · Cited by 7,350
Cited by
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., & Chatal, J.-F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8471 · Cited by 351
Self-citationRecent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A., Wessels, H. J., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03880-y · Cited by 277
Gene Therapy for Malignant Glioma: Current Clinical Status
Pulkkanen, K. J., & Yla-Herttuala, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.357 · Cited by 161
Metadata
- Authors
- Grana, C., Chinol, M., Robertson, C., Mazzetta, C., Bartolomei, M., De Cicco, C., Fiorenza, M., Gatti, M., Caliceti, P., & Paganelli, G.
- Venue
- British Journal of Cancer
- Published
- 2002-01
- Volume
- 86
- Issue
- 2
- Pages
- 207-212
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1967927421
- Cited by
- 168
- References
- 1
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study. https://app.cochat.ai/papers/10.1038/sj.bjc.6600047
- The paper
- Grana, C., Chinol, M., Robertson, C., Mazzetta, C., Bartolomei, M., De Cicco, C., Fiorenza, M., Gatti, M., Caliceti, P., & Paganelli, G. (2002). Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6600047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.